ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2022
In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance.Current microbiology · 2025Review
- The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-ResistantMicroorganisms · 2025Review
- Antimicrobial susceptibility of gram-negative strains isolated from bloodstream infections in China: Results from the study for monitoring antimicrobial resistance trends (SMART) 2018-2020.Epidemiology and infection · 2025Article
- Activity of cefiderocol in combination with tetracycline analogues against carbapenem-resistant Acinetobacter baumannii.The Journal of antibiotics · 2025Article
- The challenges of difficult-to-treatClinical microbiology reviews · 2024Review
- The Use of Cefiderocol in Gram-Negative Bacterial Infections at International Medical Center, Jeddah, Saudi Arabia.Antibiotics (Basel, Switzerland) · 2024Article
- Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak.Antibiotics (Basel, Switzerland) · 2024Article
- Antibiotic Treatment of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-ResistantOpen forum infectious diseases · 2023Article
- Antimicrobial Resistance in Ventilator-Associated Pneumonia: Predictive Microbiology and Evidence-Based Therapy.Infectious diseases and therapy · 2023Review
- Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms.Antibiotics (Basel, Switzerland) · 2023Article
- Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study.Antibiotics (Basel, Switzerland) · 2023Article
- Epidemiology and antimicrobial resistance trends ofFrontiers in public health · 2023Article
- Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
We investigated activities of cefiderocol combination therapy against carbapenem-resistant Acinetobacter baumannii (CR-AB). A total of 123 clinical isolates of CR-AB, including 44 cefiderocol-resistant isolates were tested. Cefiderocol functioned synergistically with tigecycline in most cefiderocol-susceptible isolates (84.8%, 67/79), but not with colistin or meropenem by checkerboard method. Cefiderocol functioned synergistically with tigecycline, colistin, and meropenem in 90.9% (40/44), 47.7% (21/44), and 79.5% (35/44) cefiderocol-resistant isolates, respectively. The time-kill assay and the in vivo Galleria mellonella model confirmed these observations. In summary, cefiderocol combined with tigecycline showed synergistic effects against both cefiderocol-susceptible and -resistant CR-AB, suggesting a potentially valuable combination regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.